PPA
RXDX

Parametric Portfolio Associates’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Parametric Portfolio Associates’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1.6M Buy
42,460
+8,321
+24% +$329K ﹤0.01% 2539
2021
Q4 		$1.35M Buy
+34,139
New +$1.07M ﹤0.01% 2656

Other funds holding RXDX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parametric Portfolio Associates's RXDX Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Prometheus Biosciences, Inc. Common Stock (RXDX) stake by 24% in Q1 2022, buying an estimated $329K and bringing the position to 42,460 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2539.

Parametric Portfolio Associates first reported a position in RXDX in Q4 2021 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold RXDX as of Q1 2022.

  • Parametric Portfolio Associates held 42,460 shares of Prometheus Biosciences, Inc. Common Stock worth $1.6M as of Q1 2022.
  • Parametric Portfolio Associates bought 8,321 Prometheus Biosciences, Inc. Common Stock shares in Q1 2022, an estimated $329K.
  • Prometheus Biosciences, Inc. Common Stock made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2539 holding.
  • Parametric Portfolio Associates first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.